The ability to sequence each patient’s genome in great detail, quickly and inexpensively, is changing the practice of medicine.
At Novartis Institutes for BioMedical Research (NIBR), we are dedicated to the development of therapies that improve clinical outcomes for patients. Next generation sequencing and other cutting-edge molecular characterization technologies will be important tools for discovering breakthrough therapeutics, and for delivering the right medicines to the right patients. NIBR is launching a new Next Generation Diagnostics (NGDx) group at our global headquarters in Cambridge, MA.
Dr. William Sellers, Vice President and Global Head of Oncology at NIBR, says “The NGDx team will leverage cutting-edge technologies such as next generation sequencing for characterizing human tissues, by individual lesions and by pathway signatures relevant to therapeutic response.
The goal is to develop a robust and comprehensive molecular profile for each patient. To this end, the group will begin by developing capabilities to characterize therapeutically relevant genetic lesions and pathway signatures in human cancer.”
NIBR is seeking innovative and collaborative scientists with a passion to develop and apply next generation technology to drug discovery. Opportunities exist for bioinformatics scientists, genomics scientists, computational biologists, software and systems engineers, assay development scientists, histopathologists, sample technicians, and biochemists.
Novartis Institutes for BioMedical Research is the global pharmaceutical research organization for Novartis. The NIBR research network is comprised of more than 6,000 scientists, physicians and business professionals working together across ten locations around the world to discover innovative medicines that treat diseases with high unmet medical need.
Novartis employs more than 2,000 associates in Cambridge, making it the city’s largest private employer and ideally situated in one of the leading life science communities in the world.
Novartis provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care products, cost-saving generic pharmaceuticals, consumer health products, preventive vaccines and diagnostic tools. Novartis is the only company with leading positions in each of these areas.